https://www.dovepress.com/therapeutic-potential-of-ixekizumab-in-the-treatment-of-ankylosing-spo-peer-reviewed-fulltext-article-TCRM
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170548/
https://www.ncbi.nlm.nih.gov/pubmed/32368068?dopt=Abstract
TITLE:
Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data.
DESCRIPTION:
Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data.
Ther Clin Risk Manag. 2020;16:287-297
Authors: Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F
Abstract
Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. For more than 10 years, anti-TNF biologics were successfully employed to treat AS, with marked improvement of signs and symptoms in around 60% of the patients. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis. New therapies with selective biological drugs have emerged in the treatment of this pathology. In this review, we evaluated the effects of ixekizumab, a new anti-IL-17A, that was licensed both by EMA and FDA in August 2019 for the treatment of ankylosing spondylitis. The review highlights the efficacy and safety data of the 3 randomized controlled trials (COAST V-COAST W-COAST X) and those of the extension to 52 weeks of COAST V and COAST W.
PMID: 32368068 [PubMed]
PMID:
PubMed:32368068
DATE FOUND:
05/06/20 06:30AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/32368068?dopt=Abstract
